A new study conducted by the US Center for Disease Control and Prevention (CDC) finds that Baloxavir showed broad spectrum in-vitro replication inhibition of four types of influenza viruses.
The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced a strategic partnership with Genentech. The company and ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will focus first on developing a first-in-class therapeutic for hospitalized influenza patients and a treatment for lung injuries caused by inhaling sulfur mustard gas.
Computer modeling can quickly create custom antiviral proteins programmed to shut down viruses.
The Center for Structural Genomics of Infectious Diseases (CSGID) has determined the 3-D atomic structures of more than 1,000 proteins.
Researchers have identified the first inhibitor of an enzyme seen as a potential drug target for fighting disease-causing parasites and bacteria.
The US Biomedical Advanced Research and Development Authority (BARDA) intends to ramp up investment in medical countermeasures for viral hemorrhagic fevers and chemical threat agents.
Using DNA strands, researchers developed a new testing technique that eliminates cell culture testing possibly allowing simultaneous testing of hundreds of different types of nanoparticles.
Researchers will design a prototype biocontrol system that dispatches single-cells to track down and engulf specific pathogens
The Coalition for Epidemic Preparedness Innovations intends to develop and stockpile vaccines against three known viral threats, and support the development of technology to manufacture large amounts of vaccine quickly when needed.
Engineers have created an organoid model that can be manipulated to recreate the process of immune-cell response and reproduce the function of the lymph nodes in immune cell activation.